Related Experiment Video
Updated: Jul 17, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeted therapies in non-small cell lung cancer: present and future
Jessica McLaughlin1, Jonathan Berkman2, Patrick Nana-Sinkam1
1Department of Internal Medicine, Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University Health System, Richmond, VA 23298.
Abstract:
Lung cancer is the leading cause of malignancy-related death in the United States and the second most common cancer diagnosis worldwide. In the last two decades, lung cancer treatment has evolved to include advances in the development of mutation-based targeting, immunotherapy, radiation therapy, and minimally invasive surgical techniques. The discovery of lung cancer as a molecularly heterogeneous disease has driven investigation into the development of targeted therapies resulting in improved patient outcomes. Despite these advances, there remain opportunities, through further investigation of mechanisms of resistance, to develop novel therapeutics that better direct the personalization of lung cancer therapy. In this review, we highlight developments in the evolution of targeted therapies in non-small cell lung cancer, as well as future directions shaped by emerging patterns of resistance.
Insights
Lung cancer treatments have advanced with targeted therapies and immunotherapy. Further research into resistance mechanisms is crucial for developing personalized lung cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Medical Science
Background:
- Lung cancer is a leading cause of cancer death globally.
- Recent decades show significant progress in lung cancer treatment modalities.
- Molecular heterogeneity drives the development of targeted therapies.
Purpose of the Study:
- To review the evolution of targeted therapies for non-small cell lung cancer.
- To discuss emerging patterns of resistance to current treatments.
- To outline future directions for personalized lung cancer therapy.
Main Methods:
- Literature review of targeted therapies in non-small cell lung cancer.
- Analysis of recent advances in immunotherapy and radiation therapy.
- Examination of molecular mechanisms underlying treatment resistance.
Main Results:
- Targeted therapies have improved outcomes for specific lung cancer molecular subtypes.
- Immunotherapy and advanced radiation techniques offer new treatment avenues.
- Understanding resistance mechanisms is key to overcoming treatment limitations.
Conclusions:
- Personalized lung cancer treatment has been revolutionized by targeted therapies.
- Continued investigation into resistance mechanisms is essential for future therapeutic development.
- Future strategies will focus on overcoming resistance for improved patient survival.
More Related Videos
08:03Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...